Nausea and vomiting are two of the most common side-effects of anti-cancer treatment, and the discovery and clinical application of 5-hydroxytryptamine3 receptor antagonists has transformed the management of these side effects, resulting in a much improved quality of life for cancer patients.; This text presents a detailed overview of the management of cancer-treatment induced emesis in a number of different treatment settings, and focuses on the mechanisms and use of 5-HT3 receptor antagonists. Contributions are also included from the points of view of the nurse and the patient.
Methodology of trials of nausea and vomiting; evolution of anti-emetic treatment; pharmacology of serotonin and its receptors; clinical aspects of nausea and vomiting evolution after chemotherapy; prognostic factors of chemotherapy induced nausea and vomiting; platinum induced acute nausea and vomiting; treatment of moderately emetogenic chemotherapy induced nausea and vomiting; treatment of radiotherapy induced nausea and vomiting; prevention of nausea and vomiting in repeat courses of chemotherapy; anticipatpry vomiting and nausea; delayed nausea and vomiting; are there differences between 5-HT3 receptor antagonists?; quality of life; on the receiving end - the patient's point of view; nurses' point of view; pharmacoeconomics; nausea and vomiting in children.